{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:31:03Z","timestamp":1787841063742,"version":"build-2784847793"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Disparities driven by socioeconomic factors have been shown to impact outcomes for cancer patients. We sought to explore this relationship among patients with multiple myeloma (MM) who were not considered for hematopoietic stem cell transplant in the first-line setting and how it varied over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We queried the National Cancer Database for patients diagnosed with MM between 2004 and 2016 and included only those who received systemic therapy as the first-line treatment. Enrollment rates for therapy were calculated as receipt of systemic therapy as the incident event of interest (numerator) over time to initiation of therapy (denominator) and used to calculate incident rate ratios that were further analyzed using Poisson regression analysis. A multivariate Cox proportional hazards model was constructed for survival analysis, and differences were reported as hazard ratios (HRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified 56,102 patients for enrollment analysis and 50,543 patients for survival analysis. Therapy enrollment in a multivariate model was significantly impacted by race and sex (p &lt; .005). Advanced age, earlier year of diagnosis, lack of insurance or Medicaid, and higher comorbidity were associated with poor survival (HR &gt; 1), whereas female sex, non-Hispanic black race, higher income, and treatment at an academic center were associated with improved survival (HR &lt; 1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Disparities in treatment of MM exist and are caused by a complex interplay of multiple factors, with socioeconomic factor playing a significant role. Studies exploring such determinants may help in equitable distribution of resources to overcome such differences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2020.09.005","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T01:32:16Z","timestamp":1602293536000},"page":"218-230","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Disparities in the enrollment to systemic therapy and survival for patients with multiple myeloma \u2606"],"prefix":"10.4103","volume":"14","author":[{"given":"Thejus T.","family":"Jayakrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli","family":"Bakalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zena","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney E.","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh","family":"Sadashiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-7-20241211","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2020.6548","article-title":"COVID-19 and African Americans","volume":"323","author":"Yancy","year":"2020","journal-title":"JAMA"},{"key":"R6-7-20241211","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"R7-7-20241211","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"key":"R8-7-20241211","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1023\/A:1018498414298","article-title":"Multiple myeloma among Blacks and Whites in the United States: role of cigarettes and alcoholic beverages","volume":"8","author":"Brown","year":"1997","journal-title":"Cancer Causes Control"},{"key":"R9-7-20241211","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/BF01831381","article-title":"Multiple myeloma among blacks and whites in the United States: the role of chronic antigenic stimulation","volume":"5","author":"Lewis","year":"1994","journal-title":"Cancer Causes Control"},{"key":"R10-7-20241211","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival, a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"R11-7-20241211","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cncr.29160","article-title":"Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study","volume":"121","author":"Bhatnagar","year":"2015","journal-title":"Cancer"},{"key":"R12-7-20241211","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bbmt.2014.12.024","article-title":"Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma","volume":"21","author":"Costa","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R13-7-20241211","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ajh.23753","article-title":"Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents","volume":"89","author":"Al-Hamadani","year":"2014","journal-title":"Am J Hematol"},{"key":"R14-7-20241211","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11899-017-0393-y","article-title":"Equal treatment and outcomes for everyone with multiple myeloma: are we there yet?","volume":"12","author":"Ailawadhi","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"R15-7-20241211","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med"},{"key":"R16-7-20241211","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","article-title":"Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials","volume":"8","author":"Ailawadhi","year":"2018","journal-title":"Blood Cancer J"},{"key":"R17-7-20241211","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.clml.2019.06.010","article-title":"Survival trends in young patients with multiple myeloma: a focus on racial-ethnic minorities","volume":"19","author":"Ailawadhi","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R18-7-20241211","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.21139","article-title":"The impact of race on outcomes of autologous transplantation in patients with multiple myeloma","volume":"83","author":"Verma","year":"2008","journal-title":"Am J Hematol"},{"key":"R19-7-20241211","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1038\/bcj.2016.100","article-title":"Prevalence, incidence and survival of smoldering multiple myeloma in the United States","volume":"6","author":"Ravindran","year":"2016","journal-title":"Blood Cancer J"},{"key":"R20-7-20241211","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"R23-7-20241211","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO.2017.72.4963","article-title":"Hospitalization Rates and predictors of rehospitalization among individuals with advanced cancer in the year after diagnosis","volume":"35","author":"Whitney","year":"2017","journal-title":"J Clin Oncol"},{"key":"R24-7-20241211","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jso.25315","article-title":"National trends in contralateral prophylactic mastectomy in women with locally advanced breast cancer","volume":"119","author":"Panchal","year":"2019","journal-title":"J Surg Oncol"},{"key":"R25-7-20241211","doi-asserted-by":"crossref","first-page":"e14445","DOI":"10.2196\/14445","article-title":"Disparities in electronic patient portal use in prenatal care: retrospective cohort study","volume":"21","author":"Ukoha","year":"2019","journal-title":"J Med Internet Res"},{"key":"R26-7-20241211","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment utilization for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"key":"R27-7-20241211","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/cncr.31237","article-title":"Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: a comprehensive look at racial disparities","volume":"124","author":"Ailawadhi","year":"2018","journal-title":"Cancer"},{"key":"R28-7-20241211","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/annonc\/mds023","article-title":"Changes in survival by ethnicity of patients with cancer between 1992\u2013 1996 and 2002\u20132006: is the discrepancy decreasing?","volume":"23","author":"Pulte","year":"2012","journal-title":"Ann Oncol"},{"key":"R29-7-20241211","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.clml.2015.03.001","article-title":"Racial differences in the overall survival of hairy cell leukemia in the united states: a population-based analysis of the surveillance, epidemiology, and end results database","volume":"15","author":"Giri","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R31-7-20241211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"key":"R32-7-20241211","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1038\/bcj.2014.91","article-title":"Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study","volume":"5","author":"Greenberg","year":"2015","journal-title":"Blood Cancer J"},{"key":"R33-7-20241211","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2105\/AJPH.90.8.1277","article-title":"Socioeconomic status and multiple myeloma among US blacks and whites","volume":"90","author":"Baris","year":"2000","journal-title":"Am J Public Health"},{"key":"R34-7-20241211","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00001648-199601000-00002","article-title":"Socioeconomic status and the incidence of multiple myeloma","volume":"7","author":"Koessel","year":"1996","journal-title":"Epidemiol Camb Mass"},{"key":"R35-7-20241211","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1002\/1097-0142(19841215)54:12<3085::AID-CNCR2820541246>3.0.CO;2-Z","article-title":"Race, poverty, and survival in multiple myeloma","volume":"54","author":"Savage","year":"1984","journal-title":"Cancer"},{"key":"R36-7-20241211","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.1987.5.12.1977","article-title":"Effects of socioeconomic and clinical factors on survival in multiple myeloma","volume":"5","author":"Weston","year":"1987","journal-title":"J Clin Oncol"},{"key":"R37-7-20241211","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.1987.5.10.1640","article-title":"The effects of distance from primary treatment centers on survival among patients with multiple myeloma","volume":"5","author":"Lenhard","year":"1987","journal-title":"J Clin Oncol"},{"key":"R38-7-20241211","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2407-10-74","article-title":"Trends in the incidence and survival of multiple myeloma in South East England 1985\u20132004","volume":"10","author":"Renshaw","year":"2010","journal-title":"BMC Cancer"},{"key":"R39-7-20241211","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1200\/JCO.2008.18.2006","article-title":"Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden","volume":"27","author":"Kristinsson","year":"2009","journal-title":"J Clin Oncol"},{"key":"R40-7-20241211","first-page":"713","article-title":"Socioeconomic status and survival in multiple myeloma","volume":"81","author":"Pasqualetti","year":"1990","journal-title":"Minerva Med"},{"key":"R42-7-20241211","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/j.clml.2019.03.006","article-title":"Racial and socioeconomic disparities in mantle cell lymphoma","volume":"19","author":"Shah","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R43-7-20241211","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbmt.2018.08.030","article-title":"Significant nationwide variability in the costs and hospital mortality rates of autologous stem cell transplantation for multiple myeloma: an analysis of the nationwide inpatient sample database","volume":"25","author":"Liu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R44-7-20241211","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15224","article-title":"Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas","volume":"181","author":"Olszewski","year":"2018","journal-title":"Br J Haematol"},{"key":"R45-7-20241211","doi-asserted-by":"crossref","first-page":"e0213209","DOI":"10.1371\/journal.pone.0213209","article-title":"Time to initial cancer treatment in the United States and association with survival over time: an observational study","volume":"14","author":"Khorana","year":"2019","journal-title":"PLoS ONE"},{"key":"R46-7-20241211","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620301527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620301527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.09.005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:40:30Z","timestamp":1787838030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.09.005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2020.09.005","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}